Remove 2022 Remove Blog Remove FDA Remove Informed Consent
article thumbnail

Could Self-Operated Assisted Suicide Devices Be Coming to a Town near You?

Bill of Health

While not exhaustive, this blog post explores some of the major legal issues likely to arise if a device like the Sarco were to be introduced into the United States. FDA Approval. Food and Drug Administration (FDA), which “ regulates the sale of medical device products (including diagnostic tests) in the U.S.

FDA 245
article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

Relevant matters are hereby announced as follows: As of 01 December 2022, the Electronic Certificates of Documentation for Export of APIs to the EU and Certificate of a Pharmaceutical Product will be put into use. Efforts should be made to promote and guide the use of electronic certificates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – Spring

SQA

SQA Regulatory Surveillance Summary 2022 – Spring. Brazil’s ANVISA Issues Registration Rules for Software, 01 April 2022. ANVISA has published new regulations focused on software as a medical device (SaMD), set to take effect on 01 July 2022. Agência Nacional de Vigilância Sanitária (ANVISA).

FDA 75
article thumbnail

Part 3: An Update on the Federal and State E-Roe-sion or P-Roe-tection of Abortion Rights

Healthcare Law Blog

The now-active provisions include a prohibition on abortions after 12 weeks of pregnancy (with limited exceptions), 72-hour informed consent requirements, pre-abortion gestational age verification, and reporting requirements for abortions after 12 weeks. [21] United States FDA , 2023 U.S. 5, 2022 Leg., 10, 2022).

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

This year’s Drug & Device Law Blog top ten decisions of the year reinforced preemption – the most powerful defense we can assert. Instead, Zofran turned mainly on animal studies – three Japanese studies that were not “newly acquired information” that could avoid preemption. They excluded bogus expert testimony under Fed.

FDA 105